Elasmogen Ltd

Founded in Aberdeen, Scotland, Elasmogen Ltd is a privately held biopharmaceutical company advancing a proprietary platform of next-generation biologics called soloMERs. These engineered single-domain antibody-based molecules are designed to combine biologic precision with the localised activity of small molecules, drawing on an ADC-inspired conjugate strategy that the company believes can deliver safer and more effective treatment than conventional biologics alone.

Lead Programme: ELN28 for Hidradenitis Suppurativa

Elasmogen's lead clinical candidate, ELN28, is a first-in-class dual-acting soloMER conjugate targeting Hidradenitis Suppurativa (HS), a chronic and debilitating inflammatory skin condition characterised by painful lesions, deep nodules, abscesses, skin tunnels, and scarring. HS is recognised as a major unmet need: current treatments offer only partial benefit, and the disease carries a pronounced psychosocial burden in addition to its physical impact. ELN28 combines two clinically validated agents in a single construct, aiming to address both the inflammatory drivers and tissue pathology of HS with greater precision than existing monotherapies.

Platform and Pipeline Ambitions

Beyond HS, Elasmogen's soloMER platform has potential application across a broader range of immune-mediated inflammatory diseases and solid-tumour oncology indications. The company's stated vision is to lead the next wave of innovation in immune-mediated disease, developing therapies that redefine clinical practice. Elasmogen operates at the intersection of biologic drug development and novel conjugate chemistry, positioning the soloMER format as a modular, adaptable tool for addressing conditions where existing biologics fall short.

Further information is available at elasmogen.com.